Theranos Inc. failed a second major U.S. regulatory inspection of its laboratory facilities, people familiar with the situation said, a setback the Silicon Valley blood-testing firm hasn’t disclosed to investors or patients. The failed regulatory inspection—at its one active lab at the time—has put the company at risk of a new round of sanctions, these people said. The inspection, which took place in late September, came just...

Source: Wall Street Journal January 18, 2017 03:00 UTC